Protocol Ledger

NCT05879822 · Phase II · TERMINATED

A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

Interventional Phase II clinical trial protocol NCT05879822 sponsored by Incyte in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-10-30 Enrollment: 73 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05879822
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)73 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05879822
Protocol FieldVerified Registry Value
NCT IdentifierNCT05879822
Consolidated Lead SponsorIncyte
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment73 participants (ACTUAL)
Registered Start Date2023-10-30
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI